ILMN
NASDAQ · Life Sciences Tools & Services
Illumina Inc
$126.20
+0.22 (+0.17%)
Financial Highlights (FY 2026)
Revenue
4.25B
Net Income
832.76M
Gross Margin
66.1%
Profit Margin
19.6%
Rev Growth
-1.8%
D/E Ratio
0.73
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 66.1% | 66.1% | 67.9% | 67.9% |
| Operating Margin | 18.6% | 16.7% | 8.2% | 7.1% |
| Profit Margin | 19.6% | 18.6% | 4.5% | 6.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 4.25B | 4.33B | 13.33B | 12.49B |
| Gross Profit | 2.81B | 2.86B | 9.05B | 8.48B |
| Operating Income | 790.56M | 724.40M | 1.10B | 891.35M |
| Net Income | 832.76M | 763.06M | 605.16M | 765.33M |
| Gross Margin | 66.1% | 66.1% | 67.9% | 67.9% |
| Operating Margin | 18.6% | 16.7% | 8.2% | 7.1% |
| Profit Margin | 19.6% | 18.6% | 4.5% | 6.1% |
| Rev Growth | -1.8% | -1.8% | +5.0% | +10.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.86B | 3.86B | 4.55B | 4.57B |
| Total Equity | 5.29B | 5.29B | 12.46B | 13.70B |
| D/E Ratio | 0.73 | 0.73 | 0.36 | 0.33 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 867.02M | 838.60M | 1.40B | 1.33B |
| Free Cash Flow | — | — | 480.17M | 566.05M |